◄
Path Vysion
The PathVysion HER-2 DNA Probe Kit from Vysis® is the new FDA approved assay that utilizes patented, direct labeled FISH DNA probes to yield definitive results at the molecular level.
FISH uses molecular genetic techniques to create a fluorescent DNA probe that produces a bright microscopic signal when it selectively attaches to the gene specific complementary DNA.
A different DNA probe attaches itself to the chromosome 17 centromere. The signals appear as orange and green fluorescent colors for the HER-2 gene and chromosome 17.
This enables a ratio of HER-2 to chromosome 17 signals to be calculated thereby correcting for aneuploidy of chromosome 17, which may not represent an amplified state.
Through this direct labeled FISH technology, the PathVysion HER-2 assay provides the most accurate, reliable and reproducible means for assessing HER-2 status in breast cancer.
◄
Uro Vysion
The UroVysion Kit is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss (deletion) of the 9p21locus via fluorescence in situ hybridization (FISH) in urine specimens from subjects with transitional cell carcinoma of the bladder.
Results from theUroVysion Kit are intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer.
Back to top
|
Lipa HLA
reverse hybridization technology -
fast and easy to use.
Test principle
The LiPA HLA typing tests are based on the reverse hybridization principle. Amplified biotinylated DNA material is chemically denatured, and the single strands are hybridized with specific oligonucleotide probes immobilized as parallel lines on membrane-based strips.
After hybridization, streptavidin labelled with alkaline phosphatase is added bound to any biotinylated hybrid previously formed.
|
|
LCx 
